Friday, April 29, 2016

Roth starts Foundation Healthcare at buy

Roth starts Foundation Healthcare at buy

April 19, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Foundation Healthcare (OTC:FDNH) with a “buy” rating and $6 price target. The stock closed at $3.05 on Monday. “The impetus for our buy rating is the potential of the company’s acquisition of University General Hospital (UGH) in Houston to drive increased EBITDA and EPS,” writes analyst Scott […]

FDA extends Probuphine action date

FDA extends Probuphine action date

February 19, 2016 by · Leave a Comment 

Tweet The FDA has extended its action date to consider approval of a NDA for Probuphine for the maintenance treatment of opioid addiction by the standard period to May 27 from Feb. 27. Following the Psychopharmacologic Advisory Committee meeting in January, which recommended approval of Probuphine, the FDA requested additional changes to the Risk Evaluation […]

Titan Medical offering raises $10.5-million

Titan Medical offering raises $10.5-million

February 12, 2016 by · Leave a Comment 

Tweet Titan Medical (OTCQX:TITXF; TSX:TMD) has closed a public offering of 11,670,818 units at a price of 90 cents each for gross proceeds of $10.5-million. Each unit consists of one common share and one warrant, with each warrant exercisable to purchase an additional common shares at a price of $1 for a period of 60 […]

Roth starts Bionomics at buy

Roth starts Bionomics at buy

February 3, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Bionomics (OTCQX:BNOEF; ASX:BNO) with a “buy” rating and AUD$1.50 price target. The stock closed at 32 cents on Tuesday. “We believe a significant disconnect exists on the [company’s] BNC210 opportunity alone based on clinical data in hand and the partnering potential around a drug that could address […]

TearLab estimates Q4 revenue rose 28%

TearLab estimates Q4 revenue rose 28%

February 1, 2016 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) expects to report revenue of approximately $6.8-million for the fourth quarter of 2015, up about 28% from the same quarter in 2014. In addition, TearLab estimated that a net total of 258 TearLab Osmolality Systems were added in the fourth quarter of 2015, of which 200 were under the company’s new […]

Roth starts TetraLogic Pharma at buy

Roth starts TetraLogic Pharma at buy

December 30, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of TetraLogic Pharmaceutics (NASDAQ:TLOG) with a “buy” rating and price target of $5. The stock closed at $1.42 on Wednesday. Analyst Joseph Pantginis writes that TetraLogic is about to enter a critical time in its history. In January, the company is expected to report results of two Phase […]

Roth starts Prima BioMed at buy

Roth starts Prima BioMed at buy

December 30, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and price target of $6. The stock closed at $1.11 on Wednesday. “We believe Prima is in a leading position in the development of new checkpoint inhibition pathways, based on the discovery of LAG-3 by Prima’s CMO/CSO,” writes analyst Joseph […]

Roth starts Fibrocell Science at buy

Roth starts Fibrocell Science at buy

December 22, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and 12-month target price of $14. The stock closed at $5.28 on Monday. “Leaning on 20 years of experience with autologous cell therapy, Fibrocell is establishing leadership for the treatment of rare skin and connective tissue disorders,” writes analyst Elemer […]

Roth ups Titan Pharma price target to $7.25

Roth ups Titan Pharma price target to $7.25

December 4, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target on “buy-rated” Titan Pharmaceuticals (NASDAQ:TTNP) to $7.25 from $6.50 to reflect an increased value attributed to Titan’s pipeline. The stock closed at $4.92 on Thursday. “Key takeaways [following discussions with Titan’s management] include that the Probuphine NDA appears on track, there are no changes to our […]

Roth reinitiates coverage of GW Pharma at buy

Roth reinitiates coverage of GW Pharma at buy

November 30, 2015 by · Leave a Comment 

Tweet Roth Capital Partners is reinitiating coverage of GW Pharmaceuticals (NASDAQ:GWPH) with a “buy” rating and 12-month target price of $130 per American Depository Share. The ADS closed at $84.90 on Friday GW is developing ethical pharmaceuticals derived from the cannabis plant. The company has built a one-of-its-kind plant, where it grows plants, extracts and […]

Next Page »

Email Newsletters with Constant Contact
Google+